NCT03456765

Brief Summary

A true estimation of gestational age (GA) plays animportant role in quality of maternity care such asassessment of fetal growth and to schedule the labordate. Any inaccurate estimation may lead to peri-natalmorbidity and mortality due to iatrogenic pre- or post-maturity .

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 7, 2018

Completed
5 days until next milestone

Study Start

First participant enrolled

March 12, 2018

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2019

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 20, 2019

Completed
Last Updated

January 10, 2019

Status Verified

January 1, 2019

Enrollment Period

1.1 years

First QC Date

March 5, 2018

Last Update Submit

January 8, 2019

Conditions

Gestational Age and Maturity

Outcome Measures

Primary Outcomes (1)

  • The number of participants who will have accurate GA calculated by Kidney parameters

    describes the efficiency of kidney parameters to estimate GA

    within 2 months

Interventions

UltrasoundDIAGNOSTIC_TEST

US will be made to assess kidneys

Eligibility Criteria

Age18 Years - 42 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant females
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

pregnant ladies with no medical disorders with pregnancy between 16 weeks and 40 weeks in a single living fetus

You may qualify if:

  • Single fetus.
  • pregnant ladies. with no medical disorders
  • Fetal kidneys are normally seen

You may not qualify if:

  • Medical disorders with pregnancy
  • Renal anomalies
  • Renal agesnesis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Algazeerah

Giza, Egypt

RECRUITING

MeSH Terms

Interventions

Ultrasonography

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Mahmoud Alalfy

    Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mahmoud Alalfy

CONTACT

01002611058mahmoudalalfy@ymail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital

Study Record Dates

First Submitted

March 5, 2018

First Posted

March 7, 2018

Study Start

March 12, 2018

Primary Completion

April 15, 2019

Study Completion

April 20, 2019

Last Updated

January 10, 2019

Record last verified: 2019-01

Locations

EG(1)